Celeste M Boesjes
Overview
Explore the profile of Celeste M Boesjes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boesjes C, van der Gang L, Bakker D, den Hartog Jager C, de Graaf M, de Bruin-Weller M, et al.
Clin Exp Allergy
. 2025 Feb;
55(3):260-263.
PMID: 39905630
No abstract available.
2.
Tamminga S, Van Der Wal M, Saager E, van der Gang L, Boesjes C, Hendriks A, et al.
Immunohorizons
. 2025 Jan;
9(2).
PMID: 39849992
Atopic dermatitis (AD) is characterized by dysregulated T cell immunity and skin microbiome dysbiosis with predominance of Staphylococcus aureus, which is associated with exacerbating AD skin inflammation. Specific glycosylation patterns...
3.
Boesjes C, Kamphuis E, de Graaf M, Spekhorst L, Haeck I, van der Gang L, et al.
JAMA Dermatol
. 2024 Aug;
160(10):1044-1055.
PMID: 39110432
Importance: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. Objective: To evaluate clinical effectiveness and reasons for discontinuation of...
4.
Zhang J, Boesjes C, Loman L, Kamphuis E, Romeijn M, Spekhorst L, et al.
J Am Acad Dermatol
. 2024 Apr;
91(2):300-311.
PMID: 38653344
Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients...
5.
Kamphuis E, Boesjes C, Loman L, Kamsteeg M, Haeck I, van Lynden-van Nes A, et al.
Acta Derm Venereol
. 2024 Feb;
104:adv19454.
PMID: 38323500
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety...
6.
Boesjes C, Bakker D, Knol E, de Graaf M, van Wijk F, de Bruin-Weller M
Clin Exp Allergy
. 2023 Dec;
54(4):294-296.
PMID: 38158774
No abstract available.
7.
Ragamin A, Schappin R, de Graaf M, Tupker R, Fieten K, van Mierlo M, et al.
Br J Dermatol
. 2023 Nov;
190(3):342-354.
PMID: 37936331
Background: Increased Staphylococcus aureus (SA) colonization is considered an important factor in the pathogenesis of atopic dermatitis (AD). Antibacterial therapeutic clothing aims to reduce SA colonization and AD inflammation; however,...
8.
Boesjes C, van der Gang L, Bakker D, Ten Cate T, Spekhorst L, de Graaf M, et al.
JAMA Dermatol
. 2023 Oct;
159(11):1240-1247.
PMID: 37851456
Importance: Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell lymphomas (CTCL) and lymphoid infiltrates....
9.
Spekhorst L, Boesjes C, Loman L, Zuithoff N, Bakker D, Kamphuis E, et al.
Br J Dermatol
. 2023 May;
189(3):327-335.
PMID: 37177895
Background: Limited data are available regarding patient-centred dosing of dupilumab for atopic dermatitis (AD) in daily practice. Objectives: To evaluate our patient-centred dupilumab dosing regimen in daily practice, to assess...
10.
Boesjes C, Van der Gang L, Zuithoff N, Bakker D, Spekhorst L, Haeck I, et al.
Acta Derm Venereol
. 2023 Feb;
103:adv00872.
PMID: 36794894
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the...